homepage-top-section

Frazier Life Sciences led the financing round along with new investors EQT Life Sciences, Forbion, Monograph and Wellington Management. LifeArc Ventures, Oxford Science Enterprises and the University of

The partnership will combine BioArctic’s BrainTransporter technology with an unidentified Lilly drug candidate. BioArctic is set to receive a $30m upfront payment. If the new product progresses successfully,

The approval follows a positive finding in the pivotal IRAKLIA Phase III study, which demonstrated non-inferior efficacy and pharmacokinetics compared with the intravenous (IV) formulation. It also marks

The deal value comprises an upfront payment and further payments tied to the achievement of future clinical and regulatory milestones. The proposed acquisition will add several anti-inflammatory candidates

Under the deal, Simulations Plus shareholders will receive $18.50 per share, representing a 26% premium to the 60-day volume-weighted average price as of 15 June 2026. The company’s

This approval is said to be the first in the UK for a needle-free adrenaline treatment for children aged four years and older, weighing between 15kg and less

This approval covers patients with ccRCC who are at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions. This marks the

The application covers patients with stage III colon cancer characterised by deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) or microsatellite instability-high (MSI-H). The FDA is anticipated to make

EMA has now begun reviewing its use in adults following a non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack (TIA). The validation confirms the application is complete